Aspirin in Hepatocellular Carcinoma.
Aspirin in Hepatocellular Carcinoma.
复制标题
DOI：
10.1158/0008-5472.can-21-0758
复制
发表时间：
2021-07-15
期刊：
影响因子：
11.2
通讯作者：
FitzGerald GA
中科院分区：
文献类型：
--
作者：
Ricciotti E;Wangensteen KJ;FitzGerald GA
临床前和临床研究为阿司匹林作为癌症预防剂提供了证据。令人信服的直接证据支持阿司匹林对Lynch综合征导致的结直肠癌（CRC）高风险个体的化学预防作用，而间接证据表明阿司匹林可能降低散发性CRC的风险和死亡率。有较弱的证据表明阿司匹林对所有癌症都有保护作用。然而，最近的回顾性队列研究的结果一致表明，阿司匹林作为肝细胞癌（HCC）的化学预防或辅助化疗药物的有益效果。在一般人群或选定的HCC高危人群中进行的流行病学研究表明，定期使用阿司匹林与降低HCC发病率相关。此外，阿司匹林可以作为其他疗法的辅助治疗，减少HCC复发。根据动物模型的研究，阿司匹林的抗癌作用可能与其抗血小板和抗炎活性有关。前瞻性研究是必要的，以确定阿司匹林是否应推荐给不同人群的肝癌风险的患者。
Pre-clinical and clinical studies provide evidence for aspirin as a preventative agent for cancer. Compelling direct evidence supports a chemopreventive effect of aspirin in individuals at high risk of developing colorectal cancer (CRC) due to Lynch syndrome, while indirect evidence indicates that aspirin may reduce the risk of and mortality from sporadic CRC. There is weaker evidence for a protective effect of aspirin against all cancers taken as a group. Nevertheless, the results of recent retrospective cohort studies consistently indicate a beneficial effect of aspirin as a chemopreventive or adjuvant chemotherapeutic agent in hepatocellular carcinoma (HCC). Epidemiological studies conducted in the general population or in selected populations at higher risk for HCC reveal that regular aspirin use is associated with reduced HCC incidence. In addition, aspirin may act as an adjuvant to other therapies in reducing HCC recurrence. According to studies in animal models, the cancer-preventative effect of aspirin may be related to its antiplatelet and anti-inflammatory activities. Prospective studies are warranted to determine whether aspirin should be recommended to diverse populations of patients at risk for HCC.